Primary Objective:
- To compare the tumour response rate of combination chemotherapy irinotecan/cisplatin
(IC) versus docetaxel/cisplatin (DC) in advanced NSCLC patients who responded to 3
courses of docetaxel/cisplatin.
Secondary Objectives :
- To compare the time to progression after chemotherapy treatment between the IC and DC
arms of treatment.
- To compare the toxicity profile of the IC and DC arms of treatment.